Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report

An 88-year-old Japanese man received bevacizumab for colorectal cancer with liver and peritoneal metastasis, during which nephrotic range proteinuria occurred (7.66 g/day). Renal biopsy showed endothelial damage with subendothelial swelling and a double contour of the glomerular basement membrane, w...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncology 2019-05, Vol.12 (2), p.391-400
Main Authors: Toriu, Naoya, Sekine, Akinari, Mizuno, Hiroki, Hasegawa, Eiko, Yamanouchi, Masayuki, Hiramatsu, Rikako, Hayami, Noriko, Hoshino, Junichi, Kawada, Masahiro, Suwabe, Tatsuya, Sumida, Keiichi, Sawa, Naoki, Takaichi, Kenmei, Ohashi, Kenichi, Fujii, Takeshi, Matoba, Shuichiro, Ubara, Yoshifumi
Format: Article
Language:English
Subjects:
Age
Anemia
Bevacizumab
Blood pressure
Cancer therapies
Case Report
Case reports
Colorectal cancer
Edema
Hospitals
Immunotherapy
Kidney diseases
Laboratories
Metastasis
Microscopy
Monoclonal antibodies
Nephrotic syndrome
Pathology
Patients
Proteins
Targeted cancer therapy
Thrombotic microangiopathy
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An 88-year-old Japanese man received bevacizumab for colorectal cancer with liver and peritoneal metastasis, during which nephrotic range proteinuria occurred (7.66 g/day). Renal biopsy showed endothelial damage with subendothelial swelling and a double contour of the glomerular basement membrane, which indicated a diagnosis of thrombotic microangiopathy (TMA). After bevacizumab was stopped, proteinuria decreased to 1 g/day. During the clinical course, this patient had no extrarenal manifestations. This case suggests that renal injury induced by bevacizumab is characterized by nephrotic range proteinuria and histological TMA, and is a renal-limited condition that differs from systemic TMA related to thrombotic thrombocytopenic purpura.
ISSN:1662-6575
1662-6575
DOI:10.1159/000500716